New scan spots prostate cancers standard MRI misses
NCT ID NCT04461509
First seen Mar 06, 2026 · Last updated Jun 19, 2026 · Updated 19 times
Summary
This study tested whether a high-resolution PET-MRI scan using a prostate-specific tracer (18F-PSMA) can find cancers that standard MRI might miss. 62 men with prostate cancer considering focal therapy or surgery received both scans, and results were checked with biopsies. The goal was to see if the advanced imaging improves cancer mapping before treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-PSMA (18F-DCFPyL injection, a radioactive tracer for PET imaging)
What this could lead to
If successful, this imaging approach could help doctors map prostate cancer more accurately, potentially reducing the chance of missing aggressive tumors before treatment.
What could go wrong
This is a small Phase 2 study (62 participants) focused on imaging accuracy, not treatment outcomes. The results may not apply to all prostate cancer patients or change standard care yet.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.